The Impact of Oral and Nasal Enteral Nutrition Feeding Quantity in Stroke Patients
Launched by MUHAMMAD · Mar 4, 2024
Trial Information
Current as of August 20, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare two different methods of providing nutrition to patients who have had an ischemic stroke, which is a type of stroke caused by a blockage in blood flow to the brain. The study will look at how much nutrition patients receive and their overall nutritional health using two types of feeding tubes: an Intermittent Oro-esophageal Tube and a Nasogastric Tube. Patients will be randomly assigned to one of the two groups, both of which will receive regular rehabilitation treatment. The researchers want to see if using the Oro-esophageal Tube leads to better nutrition and greater food intake compared to the Nasogastric Tube.
To participate in this trial, individuals need to be at least 18 years old and diagnosed with ischemic stroke. They must also have difficulty swallowing, confirmed by a special test, and be alert and stable. However, those with swallowing problems from other conditions or severe health issues, as well as pregnant or nursing women, will not be eligible. Participants can expect to have their nutritional intake and health monitored throughout the study to help determine the best feeding method for stroke recovery. The trial is not yet recruiting participants, so there will be additional information available when it begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age\>18 years.
- • Meeting the diagnostic criteria for ischemic stroke .
- • Dysphagia confirmed by Videofluoroscopic Swallowing Study.
- • Clear consciousness.
- • No history of prior stroke.
- • Stable vital signs.
- Exclusion Criteria:
- • Dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc.
- • Complicated with severe liver and kidney failure, tumors, or hematological disorders.
- • Simultaneously in need to undergo other therapy that might affect the outcomes of this study.
- • Pregnant or nursing females.
About Muhammad
Muhammad is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, Muhammad collaborates with leading research institutions and healthcare professionals to design and implement rigorous clinical trials. The organization prioritizes ethical standards and patient safety while striving to accelerate the development of new treatments across various therapeutic areas. Through its commitment to scientific excellence and collaboration, Muhammad aims to contribute significantly to the evolving landscape of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Nieto Luis, Master
Study Director
Site Coordinator of United Medical Group
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported